CPT1A and metabolic dysfunction-associated steatotic liver disease: As a first experimentally step, a treatment of obese pregnant mice with agonist of the AMPK-ACC-CPT1a axis or PPARα axis as well as their combination could be performed, to investigate whether this can combat the early origins of NAFLD in offspring and thereby contribute to prevent the global increase of NAFLD.